Erlotinib Application Scope

Tarceva is indicated for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease has progressed after at least one prior chemotherapy regimen. It is also used in combination with gemcitabine for the treatment of advanced pancreatic cancer in patients who are not candidates for surgical resection. This therapy works by inhibiting the epidermal growth factor receptor (EGFR) tyrosine kinase, helping to slow tumor growth and manage disease progression.

Erlotinib Characteristics

Ingredients: Erlotinib
Properties: EGFR tyrosine kinase inhibitor
Packaging Specification: 25 mg, 100 mg, 150 mg × 30 tablets/box
Storage: Store at 20–25°C; protect from moisture and light
Expiry Date: As indicated on the package
Executive Standard: FDA approved
Approval Number: NDA 021743
Date of Revision: January 2024
Manufacturer: Genentech, Inc. / Roche

Guidelines for the Use of Tarceva

Dosage and Administration:
- Recommended Dose: 150 mg orally once daily (NSCLC); 100 mg orally once daily in combination with gemcitabine (pancreatic cancer)
- Administration: Take on an empty stomach, 1 hour before or 2 hours after food
- Missed Dose: Take as soon as possible on the same day; do not double the next dose
Adverse Reactions:
- Common Adverse Reactions (≥5%):
  - Rash, diarrhea, anorexia, fatigue, nausea, vomiting, cough, dyspnea
- Serious Adverse Reactions:
  - Interstitial lung disease, severe skin reactions, hepatotoxicity
Contraindications: History of severe hypersensitivity to Tarceva or any excipients
Precautions:
- - Skin Reactions: Monitor and manage rash; may require dose adjustment
  - Hepatic Function: Monitor liver enzymes
  - Pregnancy and Lactation: Advise patients to inform healthcare provider if pregnant, planning pregnancy, breastfeeding, or planning to breastfeed

Erlotinib Interactions

CYP3A4 Inhibitors: May increase Tarceva exposure; consider dose adjustment
Acid-Reducing Agents: Proton pump inhibitors or H2 antagonists may reduce absorption; avoid concomitant use when possible

Note:

If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
This content is for reference only. Prescription drugs must be used under a doctor’s guidance and purchased from authorized sources.